Current status and future of implantable insulin pumps for the treatment of diabetes

References

• DCCT Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes 4 years after a trial of intensive therapy. N Engl. j Med. 342,381–389 (2000).
   Google Scholar
• Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomized controlled trials. Br. Med. 324,705 (2002).
   Google Scholar
• Selam JL, Raymond M, Jacquemin JL, Orsetti A, Richard JL, Mirouze J. Pharmacokinetics of insulin infused intraperitoneally via portable pumps. Diabetes Metab. 11,170–173 (1985).
   Google Scholar
• Nathan DM, Dunn FL, Bruch J et al. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am. Med. 100,412–417 (1996).
   Google Scholar
• Hepp KD. Implantable insulin pumps and metabolic control. Diabetologia 37\(Suppl. 2), S108-S111 (1994).
   Google Scholar
• Saudek CD, Selam JL, Pitt HA et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N. Engl. Med. 321,574–579 (1989).
   Google Scholar
• Selam JL, Micossi E Dunn FL, Nathan DM. Clinical trial of programmable implantable insulin pump for Type 1 diabetes. Diabetes Care 15, 877–885 (1992).
   Google Scholar
• Selam JL. Implantable insulin pumps. Lancet354, 178–179 (1999).
   Google Scholar
• Duckworth WC, Saudek CD, Giobbie-Hurder A etal. The Veterans Affairs Implantable Insulin Pump Study: effect on cardiovascular risk factors. Diabetes Care 21, 1596–602 (1998).
   Google Scholar
• Haardt MJ, Selam JL, Slama G et al. A cost—benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with Type 1 diabetes. Diabetes Carel7, 847–851 (1994).
   Google Scholar
• Hanaire-Broutin H, Broussolle C, Jeandidier N et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care 18, 388–392 (1995).
   Google Scholar
• Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicenter experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of active implants in diabetes society. Lancet 343, 514–515 (1994).
   Google Scholar
• Renard E, Bouteleau S, Jacques-Apostol D et al. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility. Diabetes Care 19, 812–817 (1996).
   Google Scholar
• Jeandidier N, Boivin S, Sapin R etal. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38, 577–584 (1995).
   Google Scholar
• Renard E, Baldet P, Picot MC etal. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors and obstructing materials. Diabetes Care 18, 300–306 (1995).
   Google Scholar
• Gin H, Melki V, Guerci B, Catargi B. Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care 24, 175 (2001).
   Google Scholar
• Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp. Clin. Endocrinol. Diabetes 109\(Suppl. 2), S333—S340 (2001).
   Google Scholar
• Renard E, Bringer J, Jacques-Apostol D et al. Complications of the pump pocket may represent a significant cause of incidents with implanted systems for intraperitoneal insulin delivery. Diabetes Care17, 1064–1066 (1994).
   Google Scholar
• Renard E, Rostane T, Carriere C etal. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. Diabetes Metab. 27, 62–65 (2001).
   Google Scholar
• Catargi B, Meyer L, Melki V, Renard E, Jeandidier N. Comparison of blood glucose stability and HbA lc between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in Type 1 diabetic patients: a pilot study. Diabetes Metab. 28, 133–137 (2002).
   Google Scholar
• DeVries JH, Eskes SA, Snoek FJ et al. Continuous intraperitoneal insulin infusion in patients with 'brittle' diabetes: favourable effects on glycaemic control and hospital stay. Diabetes Med. 19, 496–501 (2002).
   Google Scholar
• Mastrototaro JJ. The MiniMed continuous glucose monitoring system. Diabetes Thelma Tber. 2\(Suppl. 1), S13—S18 (2000).
   Google Scholar
• Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am. j Physiol. 277, E561—E571 (1999).
   Google Scholar
• Gough DA, Armour JG. Development of the implantable glucose sensor. What are the prospects and why is it taking so long? Diabetes 44, 1005–1009 (1995).
   Google Scholar
• Maran A, Crepaldi C, Tiengo A et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 25, 347–352 (2002).
   Google Scholar
• Schmidtke DVV, Freeland AC, Heller A, Bonnecaze RT. Measurement and modeling of the transient difference between blood and subcutaneous glucose concentrations in the rat after injection of insulin. Proc. Natl Acad. Sci USA 95, 294–299 (1998).
   Google Scholar
• Monsod TP, Flanagan DE, Rife F et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 25, 889–893 (2002).
   Google Scholar
• Kerner W. Implantable glucose sensors: present status and future developments. Exp. Clin. Endocrinol. Diabetes 109\(Suppl. 2), S341—S346 (2001).
   Google Scholar
• Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Carr. Opin. Pbarmacol. 2, 708–716 (2002).
   Google Scholar
• The DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N EngLj Med. 329, 977–986 (1993).
   Google Scholar
• Jaremko J, Rorstad 0. Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 21, 444–450 (1998).
   Google Scholar